Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors
Status:
Completed
Trial end date:
2019-06-12
Target enrollment:
Participant gender:
Summary
This is a phase I study of combination immunotherapy with IFN-γ and the PD-1 inhibitor
nivolumab in patients with advanced solid tumors who have progressed on at least one prior
systemic therapy, which may include prior immunotherapy.